戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 istration of a pH-responsive contrast agent (iopamidol).
2 7) or manual injection (n = 73) of 150 mL of iopamidol.
3 e margin of safety is enhanced by the use of iopamidol.
4 med in 35 (53%): 32 iomeron, 2 iobitridol, 1 iopamidol.
5  pathway was proposed for the degradation of iopamidol.
6 ctions during period 1 (10,831 injections of iopamidol 300 and 1851 injections of iopamidol 370) and
7 and 12,138 injections (10, 064 injections of iopamidol 300 and 2074 injections of iopamidol 370) duri
8 se event rates for intravenous injections of iopamidol 300 of less than 6 mL/sec but is associated wi
9                      Adverse event rates for iopamidol 300 were not affected by extrinsic warming (ex
10 vasation and overall adverse event rates for iopamidol 370 (extravasation rates: 0.27% [five of 1851]
11 ions of iopamidol 300 and 1851 injections of iopamidol 370) and 12,138 injections (10, 064 injections
12 ions of iopamidol 300 and 2074 injections of iopamidol 370) during period 2.
13 all adverse event rates for the more viscous iopamidol 370.
14 nts who underwent pulmonary angiography with iopamidol 76% were retrospectively reviewed.
15 treatment of iopromide, the potential TPs of iopamidol (a structurally similar compound to iopromide)
16 n-cardiogenic pulmonary oedema, after use of iopamidol, a widely used, low osmolar, non-ionic, radiog
17                Protocol included 150 mL oral iopamidol administered at 3 mL/sec.
18 t-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 ver
19  0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (
20 L occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol
21 nter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney
22 -osmolar contrast media (ioxaglate, iohexol, iopamidol, and ioversol) were compared.
23 ne was released during the transformation of iopamidol, and was mainly oxidized to iodate.
24 obitridol, an X-ray contrast agent analog of iopamidol but containing a single set of amide protons,
25 h 300 and 370 mg of iodine per milliliter of iopamidol by using a mechanical injector at increasing f
26 owed by contrast material-enhanced (80 mL of iopamidol) computed tomography (CT) of the chest, abdome
27  bolus of 3 mL/kg per hour for 1 hour before iopamidol contrast, followed by an infusion of 1 mL/kg p
28 ine and after administration of iodixanol or iopamidol contrast.
29 ore to 72 hours after each administration of iopamidol during a computed tomographic examination perf
30 related to the intravenous administration of iopamidol during CT examinations occurring 200 days befo
31 increase in the creatinine level; the use of iopamidol effected a relatively small rise in creatinine
32                              Chlorination of iopamidol followed a second order reaction, with an obse
33 toxicity tests indicate that chlorination of iopamidol generates a toxic mixture of high molecular we
34         Standard protocol involved 125 mL of iopamidol injected at 4 mL/sec.
35 obtained 20 and 70 seconds after intravenous iopamidol injection.
36   Prick and intradermal tests with iomeprol, iopamidol, iopromide, and iobitridol were performed in a
37  of the iodinated X-ray contrast media (ICM) iopamidol, iopromide, iohexol, iomeprol, and diatrizoate
38    The cross-reactivity between iomeprol and iopamidol is high.
39 g the ACIST CVi automated contrast injector (iopamidol; left coronary: rate of 4 mL/s, volume of 10 c
40                                              Iopamidol nephrotoxicity was negligible in this cohort o
41 nt after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or wi
42 , use of foscarnet (P =.003), and receipt of iopamidol (P =.073) each prompted a rise in serum creati
43        After intravenous injection of 100 mL iopamidol, the woman became short of breath, and a chest
44      LC-QToF-MS revealed the presence of two iopamidol TPs in unspiked AOP-treated wastewater.
45 n iopromide TPs was applied to the predicted iopamidol TPs.
46        Cross-reactivity between iomeprol and iopamidol was 22% (4/20 in patients with positive skin t
47                                              Iopamidol was administered for chemical exchange saturat
48    In the presence of aqueous chlorine, only iopamidol was transformed.
49 hallenges with alternative contrasts (mainly iopamidol) was 53% (35 tolerated out of 66 performed).
50 er generate more pressure than injections of iopamidol with 300 mg of iodine per milliliter at the sa
51                            Hand injection of iopamidol with 300 mg of iodine per milliliter generated
52                                Injections of iopamidol with 370 mg of iodine per milliliter generate
53 bility of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast mediu